Reuters -- The U.S. Food and Drug Administration’s review staff expressed doubts that GlaxoSmithKline Plc’s experimental kidney cancer drug Votrient should be approved given concerns about liver injury, documents released on Thursday said.
Reuters -- The U.S. Food and Drug Administration’s review staff expressed doubts that GlaxoSmithKline Plc’s experimental kidney cancer drug Votrient should be approved given concerns about liver injury, documents released on Thursday said.
